Edition:
India

Ionis Pharmaceuticals Inc (IONS.OQ)

IONS.OQ on NASDAQ Stock Exchange Global Select Market

51.61USD
17 Jan 2018
Change (% chg)

$0.56 (+1.10%)
Prev Close
$51.05
Open
$51.50
Day's High
$52.03
Day's Low
$50.76
Volume
229,927
Avg. Vol
401,466
52-wk High
$65.51
52-wk Low
$37.27

Select another date:

Thu, Dec 21 2017

BRIEF-Ionis Pharmaceuticals Announces Initiation Of Clinical Study Of First Orally Delivered Antisense Drug For Treatment Of Gastrointestinal Disorders

* IONIS PHARMACEUTICALS ANNOUNCES THE INITIATION OF A CLINICAL STUDY OF ITS FIRST ORALLY DELIVERED ANTISENSE DRUG FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS

BRIEF-Ionis' License Agreement For Huntington's Disease Drug Receives Hart-Scott-Rodino Clearance

* IONIS' LICENSE AGREEMENT FOR HUNTINGTON'S DISEASE DRUG, IONIS-HTT RX, RECEIVES HART-SCOTT-RODINO CLEARANCE

UPDATE 1-'Ground-breaking' new drug gives hope in Huntington's disease

LONDON, Dec 11 Scientists have for the first time fixed a protein defect that causes Huntington's disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.

BRIEF-Ionis Pharma Says Roche Has Exercised Option To License IONIS-HTT(Rx)

* IONIS PHARMACEUTICALS LICENSES IONIS-HTT RX TO PARTNER FOLLOWING SUCCESSFUL PHASE 1/2A STUDY IN PATIENTS WITH HUNTINGTON'S DISEASE

BRIEF-Ionis eligible to get nearly $800 mln in milestones from deal with Janssen

* Ionis Pharmaceuticals licenses second orally delivered antisense drug to Janssen

BRIEF-Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen

* Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS

BRIEF-Ionis Pharma, ‍Dynacure announces Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)​

* Ionis Pharmaceuticals Inc - co, ‍Dynacure announced that Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)​

BRIEF-Ionis Pharmaceuticals reports Q3 earnings per share $0.00

* Ionis Pharmaceuticals reports financial results and highlights for third quarter 2017

BRIEF-Ionis submits NDA for Inotersen to the U.S. FDA

* Ionis announces submission of new drug application (NDA) for Inotersen to the U.S. fda Source text for Eikon: Further company coverage:

BRIEF-Ionis submits marketing authorization application for Inotersen to the EMA

* Ionis announces submission of marketing authorization application for inotersen to the European Medicines Agency Source text for Eikon: Further company coverage:

Select another date: